
Brian D Robertson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/375824/publications.pdf Version: 2024-02-01



RDIAN D ROBERTSON

#	Article	IF	CITATIONS
1	Tuberculosis: a problem with persistence. Nature Reviews Microbiology, 2003, 1, 97-105.	13.6	330
2	Optimisation of Bioluminescent Reporters for Use with Mycobacteria. PLoS ONE, 2010, 5, e10777.	1.1	289
3	Three pathways for trehalose biosynthesis in mycobacteria. Microbiology (United Kingdom), 2000, 146, 199-208.	0.7	235
4	Mycobacterial Lineages Causing Pulmonary and Extrapulmonary Tuberculosis, Ethiopia. Emerging Infectious Diseases, 2013, 19, 460-463.	2.0	215
5	MMP-1 drives immunopathology in human tuberculosis and transgenic mice. Journal of Clinical Investigation, 2011, 121, 1827-1833.	3.9	197
6	Mycobacterial Mutants with Defective Control of Phagosomal Acidification. PLoS Pathogens, 2005, 1, e33.	2.1	180
7	Sensitive Detection of Gene Expression in Mycobacteria under Replicating and Non-Replicating Conditions Using Optimized Far-Red Reporters. PLoS ONE, 2010, 5, e9823.	1.1	167
8	Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Research, 2005, 33, e22-e22.	6.5	162
9	The OtsAB Pathway Is Essential for Trehalose Biosynthesis in Mycobacterium tuberculosis. Journal of Biological Chemistry, 2005, 280, 14524-14529.	1.6	143
10	Genetic variation in pathogenic bacteria. Trends in Genetics, 1992, 8, 422-427.	2.9	142
11	Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Molecular Microbiology, 1994, 11, 885-896.	1.2	140
12	The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis, 2010, 90, 361-366.	0.8	139
13	The Burden of Mycobacterial Disease in Ethiopian Cattle: Implications for Public Health. PLoS ONE, 2009, 4, e5068.	1.1	136
14	Unusual features of the cell cycle in mycobacteria: Polar-restricted growth and the snapping-model of cell division. Tuberculosis, 2007, 87, 231-236.	0.8	127
15	Mycobacterium tuberculosis Lineage Influences Innate Immune Response and Virulence and Is Associated with Distinct Cell Envelope Lipid Profiles. PLoS ONE, 2011, 6, e23870.	1.1	110
16	Cell Division Site Placement and Asymmetric Growth in Mycobacteria. PLoS ONE, 2012, 7, e44582.	1.1	104
17	Population Genomics of Mycobacterium tuberculosis in Ethiopia Contradicts the Virgin Soil Hypothesis for Human Tuberculosis in Sub-Saharan Africa. Current Biology, 2015, 25, 3260-3266.	1.8	94
18	The influence of cattle breed on susceptibility to bovine tuberculosis in Ethiopia. Comparative Immunology, Microbiology and Infectious Diseases, 2012, 35, 227-232.	0.7	92

#	Article	IF	CITATIONS
19	The Extracellular Matrix Regulates Granuloma Necrosis in Tuberculosis. Journal of Infectious Diseases, 2015, 212, 463-473.	1.9	90
20	The Lipopolysaccharide Structures of Salmonella enterica Serovar Typhimurium and Neisseria gonorrhoeae Determine the Attachment of Human Mannose-Binding Lectin to Intact Organisms. Infection and Immunity, 2000, 68, 3894-3899.	1.0	89
21	An Abundant, trans-spliced mRNA from Toxocara canis Infective Larvae Encodes a 26-kDa Protein with Homology to Phosphatidylethanolamine-binding Proteins. Journal of Biological Chemistry, 1995, 270, 18517-18522.	1.6	88
22	Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. Journal of Antimicrobial Chemotherapy, 2012, 67, 404-414.	1.3	86
23	Involvement of the gonococcal MtrE protein in the resistance of Neisseria gonorrhoeae to toxic hydrophobic agents. Microbiology (United Kingdom), 1997, 143, 2127-2133.	0.7	86
24	Cell Electrospinning: An In Vitro and In Vivo Study. Small, 2014, 10, 78-82.	5.2	81
25	A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. Journal of Antimicrobial Chemotherapy, 2012, 67, 1948-1960.	1.3	78
26	The stress-responsive chaperone α-crystallin 2 is required for pathogenesis of Mycobacterium tuberculosis. Molecular Microbiology, 2004, 55, 1127-1137.	1.2	77
27	Disruption of drug-resistant biofilms using de novo designed short α-helical antimicrobial peptides with idealized facial amphiphilicity. Acta Biomaterialia, 2017, 57, 103-114.	4.1	77
28	The role of galE in the biosynthesis and function of gonococcal lipopolysaccharide. Molecular Microbiology, 1993, 8, 891-901.	1.2	75
29	Virulence, immunopathology and transmissibility of selected strains of <i>Mycobacterium tuberculosis</i> in a murine model. Immunology, 2009, 128, 123-133.	2.0	75
30	Comparison ofMycobacterium tuberculosisGenomes Reveals Frequent Deletions in a 20 kb Variable Region in Clinical Isolates. Yeast, 2000, 1, 272-282.	0.8	74
31	Molecular mechanisms and implications for infection of lipopolysaccharide variation in Neisseria. Molecular Microbiology, 1995, 16, 847-853.	1.2	71
32	Genome wide analysis of the complete GlnR nitrogen-response regulon in Mycobacterium smegmatis. BMC Genomics, 2013, 14, 301.	1.2	66
33	Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. PLoS ONE, 2019, 14, e0212858.	1.1	66
34	Analysis of Pathogen-Host Cell Interactions in Purpura Fulminans: Expression of Capsule, Type IV Pili, and PorA by Neisseria meningitidis In Vivo. Infection and Immunity, 2002, 70, 5193-5201.	1.0	64
35	Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. Journal of Antimicrobial Chemotherapy, 2013, 68, 2118-2127.	1.3	59
36	The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence. PLoS ONE, 2012, 7, e47573.	1.1	59

BRIAN D ROBERTSON

#	Article	IF	CITATIONS
37	Unnatural amino acid analogues of membrane-active helical peptides with anti-mycobacterial activity and improved stability. Journal of Antimicrobial Chemotherapy, 2016, 71, 2181-2191.	1.3	55
38	Modelling infectious disease — time to think outside the box?. Nature Reviews Microbiology, 2006, 4, 307-312.	13.6	54
39	Alternative Luciferase for Monitoring Bacterial Cells under Adverse Conditions. Applied and Environmental Microbiology, 2005, 71, 3427-3432.	1.4	53
40	Toxocara canis: Proteolytic enzymes secreted by the infective larvae in vitro. Experimental Parasitology, 1989, 69, 30-36.	0.5	51
41	Analysis of post-translational modification of mycobacterial proteins using a cassette expression system. FEBS Letters, 2000, 473, 358-362.	1.3	50
42	Secretory acetylcholinesterases from Brugia malayi adult and microfilarial parasites. Molecular and Biochemical Parasitology, 1987, 26, 257-265.	0.5	49
43	Gonococcal rfaF mutants express Rd2chemotype LPS and do not enter epithelial host cells. Molecular Microbiology, 1995, 15, 267-275.	1.2	49
44	Deciphering the metabolic response of <scp><i>M</i></scp> <i>ycobacterium tuberculosis</i> to nitrogen stress. Molecular Microbiology, 2015, 97, 1142-1157.	1.2	49
45	Mycobacteria Modify Their Cell Size Control under Sub-Optimal Carbon Sources. Frontiers in Cell and Developmental Biology, 2017, 5, 64.	1.8	48
46	Investigation of the high rates of extrapulmonary tuberculosis in Ethiopia reveals no single driving factor and minimal evidence for zoonotic transmission of Mycobacterium bovis infection. BMC Infectious Diseases, 2015, 15, 112.	1.3	46
47	Platelets Regulate Pulmonary Inflammation and Tissue Destruction in Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 245-255.	2.5	45
48	Bioinformatic and Empirical Analysis of Novel Hypoxia-Inducible Targets of the Human Antituberculosis T Cell Response. Journal of Immunology, 2012, 189, 5867-5876.	0.4	44
49	Induction of human endothelial tissue factor expression byNeisseria meningitidis: the influence of bacterial killing and adherence to the endothelium. Microbial Pathogenesis, 1997, 22, 265-274.	1.3	41
50	Improved mycobacterial tetracycline inducible vectors. Plasmid, 2010, 64, 69-73.	0.4	41
51	A Postgenomic Approach to Identification of Mycobacterium leprae -Specific Peptides as T-Cell Reagents. Infection and Immunity, 2000, 68, 5846-5855.	1.0	40
52	Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 153-165.	2.0	40
53	Rapid detection of multidrug-resistant tuberculosis. European Respiratory Journal, 1997, 10, 1120-1124.	3.1	33
54	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	0.8	33

BRIAN D ROBERTSON

#	Article	IF	CITATIONS
55	Pathways of IL-1Î ² secretion by macrophages infected with clinical Mycobacterium tuberculosis strains. Tuberculosis, 2013, 93, 538-547.	0.8	33
56	The identification of cryptic rhamnose biosynthesis genes in Neisseria gonorrhoeae and their relationship to lipopolysaccharide biosynthesis. Journal of Bacteriology, 1994, 176, 6915-6920.	1.0	32
57	The Mycobacterium tuberculosis β-oxidation genes echA5 and fadB3 are dispensable for growth inÂvitro and inÂvivo. Tuberculosis, 2011, 91, 549-555.	0.8	31
58	A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis. Tuberculosis, 2018, 113, 231-238.	0.8	31
59	A modified agar pad method for mycobacterial live-cell imaging. BMC Research Notes, 2011, 4, 73.	0.6	28
60	Targeting the chromosome partitioning protein ParA in tuberculosis drug discovery. Journal of Antimicrobial Chemotherapy, 2010, 65, 2347-2358.	1.3	27
61	Database resources for the tuberculosis community. Tuberculosis, 2013, 93, 12-17.	0.8	27
62	Developmentally regulated expression and secretion of a polymorphic antigen by Onchocerca infective-stage larvae. Molecular and Biochemical Parasitology, 1990, 39, 203-211.	0.5	26
63	Genes associated with meningococcal capsule complex are also found in Neisseria gonorrhoeae. Journal of Bacteriology, 1996, 178, 3342-3345.	1.0	26
64	<i>Galleria mellonella -</i> a novel infection model for the <i>Mycobacterium tuberculosis</i> complex. Virulence, 2018, 9, 1126-1137.	1.8	26
65	Comparative investigation of the pathogenicity of three Mycobacterium tuberculosis mutants defective in the synthesis of p-hydroxybenzoic acid derivatives. Microbes and Infection, 2006, 8, 2245-2253.	1.0	25
66	Free Glucosylglycerate Is a Novel Marker of Nitrogen Stress in <i>Mycobacterium smegmatis</i> . Journal of Proteome Research, 2012, 11, 3888-3896.	1.8	21
67	Aspartate D48 is essential for the GlnR-mediated transcriptional response to nitrogen limitation in Mycobacterium smegmatis. FEMS Microbiology Letters, 2012, 330, 38-45.	0.7	21
68	Galleria mellonella: An Infection Model for Screening Compounds Against the Mycobacterium tuberculosis Complex. Frontiers in Microbiology, 2019, 10, 2630.	1.5	20
69	Analysis of the function of mycobacterial DnaJ proteins by overexpression and microarray profiling. Tuberculosis, 2004, 84, 180-187.	0.8	19
70	In Vitro and In Vivo Interrogation of Bioâ€sprayed Cells. Small, 2012, 8, 2495-2500.	5.2	19
71	Genetic and pharmacological inhibition of inflammasomes reduces the survival of Mycobacterium tuberculosis strains in macrophages. Scientific Reports, 2020, 10, 3709.	1.6	19
72	Susceptibility of <i>Mycobacterium tuberculosis</i> -infected host cells to phospho-MLKL driven necroptosis is dependent on cell type and presence of TNFα. Virulence, 2017, 8, 1820-1832.	1.8	18

BRIAN D ROBERTSON

#	Article	IF	CITATIONS
73	Ultra-Short Antimicrobial Peptoids Show Propensity for Membrane Activity Against Multi-Drug Resistant Mycobacterium tuberculosis. Frontiers in Microbiology, 2020, 11, 417.	1.5	18
74	MICROBIOLOGY:TB Vaccines: Global Solutions for Global Problems. Science, 1999, 284, 1479-1480.	6.0	17
75	Bioluminescent Monitoring of In Vivo Colonization and Clearance Dynamics by Light-Emitting Bacteria. Methods in Molecular Biology, 2009, 574, 137-153.	0.4	17
76	Characterization of Two New Multidrug-Resistant Strains of Mycobacterium smegmatis: Tools for Routine In Vitro Screening of Novel Anti-Mycobacterial Agents. Antibiotics, 2019, 8, 4.	1.5	15
77	Deciphering the response of Mycobacterium smegmatis to nitrogen stress using bipartite active modules. BMC Genomics, 2013, 14, 436.	1.2	14
78	Molecular Analysis of Mycobacterium tuberculosis Strains with an Intact pks15/1 Gene in a Rural Community of Mexico. Archives of Medical Research, 2008, 39, 809-814.	1.5	13
79	Adenylylation of mycobacterial Glnk (PII) protein is induced byÂnitrogen limitation. Tuberculosis, 2013, 93, 198-206.	0.8	12
80	Mammalian lectin arrays for screening host–microbe interactions. Journal of Biological Chemistry, 2020, 295, 4541-4555.	1.6	12
81	Rifampin- or Capreomycin-Induced Remodeling of the <i>Mycobacterium smegmatis</i> Mycolic Acid Layer Is Mitigated in Synergistic Combinations with Cationic Antimicrobial Peptides. MSphere, 2018, 3, .	1.3	11
82	Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies. Emerging Topics in Life Sciences, 2020, 4, 581-600.	1.1	11
83	Genomics: Leprosy $\hat{a} \in \hat{~}$ a degenerative disease of the genome. Current Biology, 2001, 11, R381-R383.	1.8	10
84	Innate Immune Responses of Galleria mellonella to Mycobacterium bovis BCG Challenge Identified Using Proteomic and Molecular Approaches. Frontiers in Cellular and Infection Microbiology, 2021, 11, 619981.	1.8	10
85	An Auto-luminescent Fluorescent BCG Whole Blood Assay to Enable Evaluation of Paediatric Mycobacterial Responses Using Minimal Blood Volumes. Frontiers in Pediatrics, 2019, 7, 151.	0.9	9
86	A novel biosafety level 2 compliant tuberculosis infection model using a Δ <i>leuD</i> Δ <i>panCD</i> double auxotroph of <i>Mycobacterium tuberculosis</i> H37Rv and <i>Galleria mellonella</i> . Virulence, 2020, 11, 811-824.	1.8	9
87	Mycobacterium tuberculosis antigen 85B and ESAT-6 expressed as a recombinant fusion protein in Mycobacterium smegmatis elicits cell-mediated immune response in a murine vaccination model. Molecular Immunology, 2013, 54, 278-283.	1.0	8
88	A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy. Scientific Reports, 2021, 11, 4201.	1.6	8
89	Mycobacterial Growth. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a021097.	2.9	7
90	Use of the Invertebrate Calleria mellonella as an Infection Model to Study the Mycobacterium tuberculosis Complex. Journal of Visualized Experiments, 2019, , .	0.2	7

#	Article	IF	CITATIONS
91	Characterising resuscitation promoting factor fluorescent-fusions in mycobacteria. BMC Microbiology, 2018, 18, 30.	1.3	5
92	Analysis of ParAB dynamics in mycobacteria shows active movement of ParB and differential inheritance of ParA. PLoS ONE, 2018, 13, e0199316.	1.1	4
93	Systems biology and its impact on anti-infective drug development. , 2007, 64, 1-20.		3
94	Approaches to combat tuberculosis. Current Opinion in Biotechnology, 1998, 9, 650-652.	3.3	2
95	Visualization of microarray results to assist interpretation. Tuberculosis, 2004, 84, 275-281.	0.8	2
96	Optimisation of inhaled tuberculosis therapies and implications for host–pathogen interactions. Tuberculosis, 2011, 91, 64.	0.8	2
97	Understanding the evolution of Mycobacterium tuberculosis lineages using an integrated genomics and metabolomics approach. Access Microbiology, 2020, 2, .	0.2	Ο